
A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but the assessment of the drug in adolescents has been lacking. 201 participants underwent randomization, and 180 (90%) completed treatment. All but one of the participants had obesity. Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a more significant reduction in BMI than lifestyle intervention alone.
Like
Save
Share